Goldman SachsGSTOP PICKMar 02, 2016Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
(A Top Pick March 24/15. Down 18.22%.) This is a wonderful bank. The stock has been unduly hit. Over the last 4 months everybody was saying the IPO market was done and there are no more initial public offerings and the company can’t make any money. Quietly, without people noticing, the bond market has been running at a record pace for the last 2 months, and this company is making money on that. Trading at 8X BV and the free cash flow is strong. Dividend yield of 1.69%.